GSA Capital Partners LLP acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the third quarter, HoldingsChannel.com reports. The firm acquired 30,464 shares of the company’s stock, valued at approximately $1,337,000.
Several other large investors have also recently added to or reduced their stakes in the stock. Assetmark Inc. grew its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the last quarter. Janney Capital Management LLC bought a new position in Structure Therapeutics in the 3rd quarter worth about $290,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Structure Therapeutics by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,460 shares of the company’s stock valued at $503,000 after purchasing an additional 5,707 shares during the period. abrdn plc raised its holdings in shares of Structure Therapeutics by 132.7% during the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.
Structure Therapeutics Stock Performance
Shares of Structure Therapeutics stock opened at $36.37 on Thursday. The business has a fifty day simple moving average of $39.48 and a 200-day simple moving average of $39.87. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $66.38.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on GPCR
Structure Therapeutics Profile
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Recommended Stories
- Five stocks we like better than Structure Therapeutics
- Energy and Oil Stocks Explained
- Rocket Lab is the Right Stock for the Right Time
- How to Use High Beta Stocks to Maximize Your Investing Profits
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report).
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.